Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Artery | 5 | 2020 | 440 | 1.210 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 3 | 2019 | 30 | 1.170 |
Why?
|
| Hypertension, Pulmonary | 5 | 2020 | 435 | 1.060 |
Why?
|
| Vasoconstriction | 4 | 2020 | 102 | 0.840 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2023 | 9 | 0.840 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2019 | 160 | 0.580 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 502 | 0.550 |
Why?
|
| Patient Admission | 1 | 2017 | 187 | 0.510 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2019 | 598 | 0.470 |
Why?
|
| rho-Associated Kinases | 1 | 2014 | 53 | 0.450 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2017 | 206 | 0.440 |
Why?
|
| Veterans | 2 | 2023 | 1757 | 0.430 |
Why?
|
| Antibodies, Neutralizing | 3 | 2021 | 466 | 0.430 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2009 | 96 | 0.410 |
Why?
|
| Heart Diseases | 1 | 2017 | 494 | 0.400 |
Why?
|
| Inclusion Bodies | 2 | 2009 | 48 | 0.390 |
Why?
|
| DNA | 1 | 2014 | 1599 | 0.320 |
Why?
|
| Autophagy | 1 | 2011 | 396 | 0.290 |
Why?
|
| Lung Diseases | 1 | 2011 | 384 | 0.280 |
Why?
|
| Stress, Physiological | 1 | 2009 | 257 | 0.270 |
Why?
|
| Ventricular Function, Right | 2 | 2019 | 111 | 0.250 |
Why?
|
| Antiviral Agents | 2 | 2021 | 747 | 0.250 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 2538 | 0.250 |
Why?
|
| Adenosine Monophosphate | 2 | 2021 | 43 | 0.230 |
Why?
|
| Alanine | 2 | 2021 | 181 | 0.230 |
Why?
|
| Double-Blind Method | 3 | 2021 | 1627 | 0.210 |
Why?
|
| Aged | 7 | 2023 | 19678 | 0.200 |
Why?
|
| Male | 14 | 2023 | 61266 | 0.190 |
Why?
|
| Phenylephrine | 2 | 2019 | 38 | 0.180 |
Why?
|
| Peritoneal Dialysis | 1 | 2023 | 119 | 0.180 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 37 | 0.180 |
Why?
|
| Hydra | 1 | 2020 | 3 | 0.170 |
Why?
|
| Aorta, Thoracic | 2 | 2017 | 528 | 0.170 |
Why?
|
| Pulmonary Fibrosis | 2 | 2019 | 105 | 0.170 |
Why?
|
| Endothelium | 1 | 2020 | 72 | 0.170 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 62 | 0.170 |
Why?
|
| Extracellular Vesicles | 1 | 2020 | 46 | 0.170 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2019 | 38 | 0.160 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2014 | 355 | 0.150 |
Why?
|
| Cells, Cultured | 2 | 2019 | 3062 | 0.150 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2020 | 113 | 0.150 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 375 | 0.150 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 136 | 0.150 |
Why?
|
| Disease Progression | 3 | 2020 | 2053 | 0.140 |
Why?
|
| Cytokines | 2 | 2015 | 1292 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 1327 | 0.130 |
Why?
|
| Survival Rate | 2 | 2020 | 2035 | 0.130 |
Why?
|
| Female | 10 | 2023 | 66533 | 0.130 |
Why?
|
| Humans | 17 | 2023 | 124777 | 0.130 |
Why?
|
| Mice | 7 | 2019 | 17752 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1017 | 0.130 |
Why?
|
| Action Potentials | 1 | 2019 | 501 | 0.130 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2020 | 401 | 0.120 |
Why?
|
| Adenosine | 1 | 2016 | 128 | 0.120 |
Why?
|
| Echocardiography | 2 | 2019 | 1052 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 359 | 0.120 |
Why?
|
| Emphysema | 1 | 2015 | 67 | 0.120 |
Why?
|
| Heart Atria | 1 | 2017 | 316 | 0.120 |
Why?
|
| Animals | 9 | 2020 | 34190 | 0.120 |
Why?
|
| Hypoxia | 1 | 2016 | 248 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 4430 | 0.110 |
Why?
|
| Vascular Remodeling | 3 | 2020 | 41 | 0.110 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Heart Ventricles | 1 | 2019 | 767 | 0.110 |
Why?
|
| Calcium | 1 | 2019 | 1099 | 0.110 |
Why?
|
| Adult | 7 | 2023 | 29457 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2023 | 4783 | 0.110 |
Why?
|
| Protein Transport | 3 | 2009 | 369 | 0.110 |
Why?
|
| Pneumonia | 2 | 2014 | 326 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2023 | 16298 | 0.100 |
Why?
|
| Comorbidity | 1 | 2017 | 1531 | 0.100 |
Why?
|
| Vasodilation | 1 | 2013 | 190 | 0.100 |
Why?
|
| Mice, Knockout | 3 | 2014 | 3754 | 0.100 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 4357 | 0.100 |
Why?
|
| Middle Aged | 5 | 2021 | 26700 | 0.090 |
Why?
|
| Enzyme Activation | 2 | 2009 | 626 | 0.090 |
Why?
|
| Intention to Treat Analysis | 2 | 2020 | 64 | 0.090 |
Why?
|
| Prevalence | 1 | 2017 | 2451 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 523 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2021 | 342 | 0.090 |
Why?
|
| Smoking | 1 | 2015 | 1044 | 0.080 |
Why?
|
| Incidence | 1 | 2017 | 3144 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2009 | 90 | 0.080 |
Why?
|
| Rhodamines | 1 | 2009 | 22 | 0.080 |
Why?
|
| Subcellular Fractions | 1 | 2009 | 98 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2014 | 1348 | 0.080 |
Why?
|
| Genotype | 1 | 2014 | 2557 | 0.080 |
Why?
|
| Bronchi | 1 | 2009 | 98 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 1163 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 1708 | 0.070 |
Why?
|
| Cell Survival | 1 | 2009 | 807 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2021 | 12333 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2009 | 446 | 0.060 |
Why?
|
| Lung | 3 | 2020 | 1491 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2009 | 911 | 0.060 |
Why?
|
| Adolescent | 1 | 2021 | 19326 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2022 | 6 | 0.050 |
Why?
|
| Nucleocapsid | 1 | 2022 | 7 | 0.050 |
Why?
|
| Hospitalization | 2 | 2020 | 1781 | 0.050 |
Why?
|
| United States | 1 | 2017 | 10883 | 0.050 |
Why?
|
| Medical Futility | 1 | 2021 | 37 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2014 | 4543 | 0.050 |
Why?
|
| Kallikrein-Kinin System | 1 | 2020 | 2 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 3448 | 0.040 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2020 | 6 | 0.040 |
Why?
|
| Clathrin | 1 | 2020 | 24 | 0.040 |
Why?
|
| Phenyl Ethers | 1 | 2020 | 9 | 0.040 |
Why?
|
| Endothelin-1 | 1 | 2020 | 40 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2014 | 266 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 102 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2021 | 437 | 0.040 |
Why?
|
| Endocytosis | 1 | 2020 | 124 | 0.040 |
Why?
|
| Cell Death | 1 | 2020 | 240 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 541 | 0.040 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2019 | 11 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2020 | 262 | 0.040 |
Why?
|
| Bleomycin | 1 | 2019 | 150 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2019 | 77 | 0.040 |
Why?
|
| Ventricular Remodeling | 1 | 2019 | 181 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 384 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2020 | 457 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 462 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 492 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 1230 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2020 | 526 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2016 | 98 | 0.030 |
Why?
|
| Models, Animal | 1 | 2017 | 465 | 0.030 |
Why?
|
| Neoplasms | 1 | 2009 | 2788 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 251 | 0.030 |
Why?
|
| STAT6 Transcription Factor | 1 | 2014 | 36 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2014 | 62 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 1017 | 0.030 |
Why?
|
| Calcimycin | 1 | 2013 | 26 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 199 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 313 | 0.030 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2013 | 59 | 0.030 |
Why?
|
| Indomethacin | 1 | 2013 | 84 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2014 | 142 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 1105 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 3063 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 510 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 471 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 701 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 803 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2009 | 41 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2009 | 58 | 0.020 |
Why?
|
| Half-Life | 1 | 2009 | 157 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2009 | 122 | 0.020 |
Why?
|
| Detergents | 1 | 2008 | 24 | 0.020 |
Why?
|
| Histone Deacetylase 6 | 1 | 2008 | 7 | 0.020 |
Why?
|
| Dyneins | 1 | 2008 | 13 | 0.020 |
Why?
|
| Epithelium | 1 | 2009 | 362 | 0.020 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2008 | 43 | 0.020 |
Why?
|
| Child | 2 | 2023 | 24453 | 0.020 |
Why?
|
| Cytosol | 1 | 2008 | 161 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 114 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2008 | 174 | 0.020 |
Why?
|
| Microtubules | 1 | 2008 | 197 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2008 | 354 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 2901 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 756 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 356 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 4607 | 0.020 |
Why?
|
| Asthma | 1 | 2014 | 748 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2009 | 1625 | 0.020 |
Why?
|
| Heart Failure | 1 | 2019 | 2301 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 1750 | 0.010 |
Why?
|
| Hypertension | 1 | 2013 | 1314 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1461 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 2772 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 3342 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 4261 | 0.010 |
Why?
|